Introduction
There is an ongoing debate on the risks and benefits of the use of continuous intravenous anesthetic drugs (cIVADs) for treatment of refractory status epilepticus (RSE) [
1]. As prolonged seizures have been linked to neuronal damage in animal models [
2,
3] and to poor functional outcome in humans [
4,
5], guidelines advocate cIVADs as third-line therapy for rapid termination of seizures [
6]. Both the Neurocritical Care Society and the European Federation of Neurological Societies, however, acknowledge a shortage of data supporting this therapeutic approach [
7,
8]. Recent studies reported a negative impact of cIVAD therapy on outcome in RSE [
9‐
11]. These studies compared status epilepticus (SE) cohorts treated with and without cIVADs, whereas the factors associated with negative outcome specifically among patients with RSE treated with cIVADs have gained little attention by now. In the present study, we sought to examine the effects of timing of initiation of cIVADs on outcome in RSE by using a 48-h cutoff after RSE onset for definition of early and late use of cIVADs. As cIVADs were reported to be particularly hazardous when used for treatment of milder forms of SE [
9], we also analyzed subgroups defined by RSE severity graded by the Status Epilepticus Severity Score (STESS) and the variables included in the STESS [
12].
Discussion
In this study, we aimed to analyze the impact of timing of anesthetic therapy on the clinical course and the prognosis of RSE and found early initiation of cIVADs to be associated with higher chance of good outcome at last follow-up. This is one of only a few studies exclusively focusing on RSE episodes treated with continuous anesthetics, and several aspects of our results deserve attention.
First, we found reduced mental status and GCSE to be more frequent among patients who received treatment with cIVADs early. This probably reflects the fact that time of initiation of such therapy may be driven by clinical necessity rather than a specific treatment strategy in many cases, including those when patients have persisting convulsions after administration of two lines of non-anesthetic AEDs or require intubation for airway protection [
17]. Both severely lowered levels of consciousness and generalized convulsive seizures are known predictors of negative outcome in SE [
15,
18,
19]. Thus, although unfavorable prognosticators were more common among patients with early initiation of cIVADs, these individuals had better outcome. As there were no differences in baseline characteristics accounting for this fact, it appears plausible that this observation is related to the time of cIVAD initiation, especially because this factor was an independent predictor of outcome upon multivariable analysis.
Second, the choice of anesthetics administered requires discussion. Early cIVAD therapy was a negative predictor for the use of thiopental. Previous research found that, compared with other anesthetics, thiopental for RSE was associated with higher risk of complications, prolonged mechanical ventilation [
20], duration of intensive care unit and overall hospital stay, and worse short- and long-term outcome [
21]. Therefore, both clinical course and outcome could depend more on the choice of a specific anesthetic agent than on the time of initiation of cIVAD therapy. However, the decision to apply barbiturates may be influenced by a higher degree of seizure refractoriness suspected, especially as previous research found their use for RSE to be a surrogate for treatment aggressiveness [
22]. Refractoriness to therapy in SE is known to increase with the duration of seizures [
23] and therefore late use of anesthetics could lead to administration of a more hazardous agent, thus linking late use of cIVADs to poorer outcome.
Third, stratification of the study population according to the STESS and its components revealed that the positive effect of early cIVAD initiation in the overall cohort appeared driven primarily by the subgroups of individuals with STESS less than 3, age less than 65 years, and a history of seizures. A potential association between low RSE severity and good outcome following early cIVAD use deserves particular attention, given that previous reports advocated reserving aggressive therapy for patients scoring high on the STESS because of the risk-benefit ratio [
12]. Our findings, however, support the opposite approach as rapid treatment escalation was related to positive outcome specifically among patients with RSE of low severity as indicated by a STESS less than 3. This finding is intriguing, but our results along with observations from previous studies offer a plausible explanation for it: (1) RSE duration was significantly shorter in the early cIVAD cohort in our study, (2) previous research found shorter RSE duration to be an independent predictor of positive outcome among RSE patients receiving cIVADs [
24], and (3) low STESS frequently implies a more benign RSE etiology and therefore a larger impact of seizure duration on outcome [
5].
To our knowledge, there are no studies that specifically aimed to examine the impact of cIVAD timing on outcome in RSE. In recent research on the effects of high versus low continuous intravenous midazolam (cIV-MDZ) infusion doses on RSE course and outcome, treatment was started significantly earlier in the high-dose cohort and these patients were less likely to die during hospital stay or to have withdrawal seizures; however, in a multivariable model, time of cIV-MDZ treatment was not an independent outcome predictor [
25].
A secondary analysis of the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) characterized the influence of early (defined as performed pre-hospital or within 30 min of emergency department arrival) versus late endotracheal intubation on outcome in SE and observed late intubation to be associated with higher mortality [
26]. This finding points in the same direction as our observations, but, given major differences in inclusion criteria and in the definition of
early, it is difficult to compare study results.
Limitations
Our study has several clear limitations that need to be considered. The sample size is small, which is particularly problematic in a disorder as heterogenic as RSE. Data were collected retrospectively, and the medical records did not contain detailed enough information to determine the exact time of RSE cessation after initiation of cIVADs in all cases; therefore, we had to estimate RSE duration in days and not in hours. Furthermore, we could (with certainty) only tell that but not clearly assess the reasons why cIVADs were applied early or late. Some patients may have received cIVADs because they required intubation for airway protection or mechanical ventilation and not primarily for seizure control. Therefore, confounders not considered in our study may have substantially influenced therapeutic decisions and outcome, introducing the risk of bias into our results. Furthermore, we did not assess cIVAD dosing, and treatment of RSE with cIVADs did not follow a specific protocol in our institution during the early years of the study period. Setting the cutoff between early and late cIVAD treatment at 48 h after RSE onset represents an arbitrary definition which may appear inappropriate in light of guidelines advocating rapid treatment escalation. However, in our experience, a conservative approach in the first 48 h may represent a viable therapeutic option in non-convulsive RSE episodes, including those arising from GCSE either spontaneously or after initial treatment. The primary outcome measure of this study was not based on data collected at defined time points but relied on last available follow-up findings. Although follow-up durations were variable, they did not differ significantly between any of the cohorts compared. Furthermore, the validity of the primary outcome measure is supported by a trend toward higher chance of better outcome in the early cIVAD cohort already at time of discharge.